The m6A level was inversely correlated with TNM (Tumor, Node, and Metastasis) and clinical stage, whereas positively with tumor differentiation in KRAS mutant patients, but not in those with Kras wildtype (Fig. 1C). This evidence concerns the gene KRAS and neoplasm.